These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 4052864)

  • 1. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB; de Veber LL; Sulh HM
    Can J Ophthalmol; 1985 Jun; 20(4):153-6. PubMed ID: 4052864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.
    Olivieri NF; Buncic JR; Chew E; Gallant T; Harrison RV; Keenan N; Logan W; Mitchell D; Ricci G; Skarf B
    N Engl J Med; 1986 Apr; 314(14):869-73. PubMed ID: 3485251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vision and hearing during deferoxamine therapy.
    Cohen A; Martin M; Mizanin J; Konkle DF; Schwartz E
    J Pediatr; 1990 Aug; 117(2 Pt 1):326-30. PubMed ID: 2380834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.
    Gallant T; Boyden MH; Gallant LA; Carley H; Freedman MH
    Am J Med; 1987 Dec; 83(6):1085-90. PubMed ID: 3503576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients.
    Chen SH; Liang DC; Lin HC; Cheng SY; Chen LJ; Liu HC
    J Pediatr Hematol Oncol; 2005 Dec; 27(12):651-3. PubMed ID: 16344669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment.
    Triantafyllou N; Fisfis M; Sideris G; Triantafyllou D; Rombos A; Vrettou H; Mantouvalos V; Politi C; Malliara S; Papageorgiou C
    Acta Neurol Scand; 1991 May; 83(5):306-8. PubMed ID: 1648295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hearing impairment during deferoxamine therapy for thalassemia major.
    Argiolu F; Diana G; Avignone A; Cao A; Di Ninni S
    J Pediatr; 1991 May; 118(5):826-7. PubMed ID: 2019945
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evaluation of auditory function in homozygous beta-thalassemia].
    Stura M; Arigliani R; Molinari AC; Tarantino V
    Pediatr Med Chir; 1986; 8(5):703-5. PubMed ID: 3601700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
    Bene C; Manzler A; Bene D; Kranias G
    Clin Nephrol; 1989 Jan; 31(1):45-8. PubMed ID: 2783668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
    Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
    Cases A; Kelly J; Sabater F; Torras A; Griño MC; Lopez-Pedret J; Revert L
    Nephron; 1990; 56(1):19-23. PubMed ID: 2234245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
    Barratt PS; Toogood IR
    Med J Aust; 1987 Aug; 147(4):177-9. PubMed ID: 3657630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
    Porter JB; Jaswon MS; Huehns ER; East CA; Hazell JW
    Br J Haematol; 1989 Nov; 73(3):403-9. PubMed ID: 2605127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

  • 15. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
    Koren G; Kochavi-Atiya Y; Bentur Y; Olivieri NF
    Int J Hematol; 1991 Oct; 54(5):371-5. PubMed ID: 1756248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual loss in patient on high-dose subcutaneous desferrioxamine.
    Borgna-Pignatti C; De Stefano P; Broglia AM
    Lancet; 1984 Mar; 1(8378):681. PubMed ID: 6142370
    [No Abstract]   [Full Text] [Related]  

  • 19. [Longitudinal growth of patients with homozygote beta-thalassemia during continuous subcutaneous infusion of deferoxamine].
    Krüger N; Stubbe P; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1986 Jan; 111(5):176-81. PubMed ID: 3943469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid recovery with oral zinc sulphate in deferoxamine-induced presumed optic neuropathy and hearing loss.
    Pinna A; Corda L; Carta F
    J Neuroophthalmol; 2001 Mar; 21(1):32-3. PubMed ID: 11315979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.